Altimmune (ALT) Depreciation & Amortization - Total (2012 - 2017)
Altimmune (ALT) reported Depreciation & Amortization - Total of $33007.0 for Q1 2017, down 12.45% year-over-year from $37701.0 in Q1 2016, and little changed quarter-over-quarter from $33066.0 in Q4 2016.
Altimmune (ALT) Depreciation & Amortization - Total (2012 - 2017) Analysis & Trends
Altimmune (ALT) has 6 years of Depreciation & Amortization - Total data on file, last reported at $33007.0 in Q1 2017.
- Depreciation & Amortization - Total for Q1 2017 came in at $33007.0, down 12.45% year-over-year; the trailing twelve-month figure through Dec 2017 was $33007.0 (down 76.99% YoY), and the FY2016 annual result was $143437.0, up 1.29% from the prior year.
- Depreciation & Amortization - Total was little changed at $33007.0 in Q1 2017 per ALT's latest filing, from $33066.0 in the prior quarter.
- Over five years, Depreciation & Amortization - Total peaked at $52602.0 in Q1 2013 and troughed at $32235.0 in Q3 2016.
- A 5-year average of $38264.3 and a median of $37106.0 in 2015 frame the typical range for Depreciation & Amortization - Total.
- The sharpest annual moves came in 2013 and 2016: Depreciation & Amortization - Total slumped 38.45% in 2013, then grew 10.22% in 2016.
- A 5-year view of Depreciation & Amortization - Total shows it stood at $43438.0 in 2013, then retreated by 15.54% to $36686.0 in 2014, then declined by 10.58% to $32806.0 in 2015, then gained by 0.79% to $33066.0 in 2016, then fell by 0.18% to $33007.0 in 2017.
- Business Quant data shows ALT's Depreciation & Amortization - Total at $33007.0 in Q1 2017, $33066.0 in Q4 2016, and $32235.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Tot) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Altimmune | 336.67 Mn | 336.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 33,007.00 |
| Dec 31, 2016 | 33,066.00 |
| Sep 30, 2016 | 32,235.00 |
| Jun 30, 2016 | 40,435.00 |
| Mar 31, 2016 | 37,701.00 |
| Dec 31, 2015 | 32,806.00 |
| Sep 30, 2015 | 35,005.00 |
| Jun 30, 2015 | 36,687.00 |
| Mar 31, 2015 | 37,106.00 |
| Dec 31, 2014 | 36,686.00 |
| Sep 30, 2014 | 37,125.00 |
| Jun 30, 2014 | 36,208.00 |
| Mar 31, 2014 | 39,939.00 |
| Dec 31, 2013 | 43,438.00 |
| Sep 30, 2013 | 44,593.00 |
| Jun 30, 2013 | 41,854.00 |
| Mar 31, 2013 | 52,602.00 |
| Dec 31, 2012 | 69,105.00 |
| Sep 30, 2012 | 72,453.00 |